Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) was the recipient of a significant growth in short interest in January. As of January 30th, there was short interest totaling 677,542 shares, a growth of 324,082.8% from the January 15th total of 209 shares. Based on an average trading volume of 7,284,850 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 7,284,850 shares, the days-to-cover ratio is presently 0.1 days.
Enzolytics Price Performance
Shares of ENZC opened at $0.00 on Thursday. Enzolytics has a one year low of $0.00 and a one year high of $0.00.
About Enzolytics
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
See Also
- Five stocks we like better than Enzolytics
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Trump’s Hand-Written Letter Will Shock his Haters
- Trump’s national nightmare is here
- ISPC: From Small Cap to Life Sciences Market Disruptor!
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
